How were Neuren Pharmaceuticals' earnings last quarter?

Neuren Pharmaceuticals Limited (ASX:NEU) issued its quarterly earnings results on Wednesday, February, 27th. The company reported $0.03 earnings per share for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 88.06% and a net margin of 70.26%.

What other stocks do shareholders of Neuren Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG) , Magellan Financial Group (MFG) , Medlab Clinical (MDC) , FBR (FBR) , Embark Early Education (EVO) , Dacian Gold (DCN) , Constellation Technologies (CT1) , Afterpay (APT) and Alkane Resources (ALK) .

Neuren Pharmaceuticals Stock Price, News & Analysis (ASX:NEU)

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 57,935 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Neuren Pharmaceuticals Stock (ASX:NEU)

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.

NEU Stock News Headlines

November 6, 2023 | morningstar.com

Neuren Pharmaceuticals Ltd NEU

November 3, 2023 | finance.yahoo.com

Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

October 5, 2023 | fool.com.au

Bell Potter says these are the best ASX shares to buy in October

September 26, 2023 | msn.com

Acadia Pharmaceuticals: Difficult Market Masks Progress

September 7, 2023 | markets.businessinsider.com

Wilsons downgrades Mayne Pharma Group (MAYNF) to a Sell

August 31, 2023 | markets.businessinsider.com

Bell Potter Keeps Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)

August 30, 2023 | finance.yahoo.com

Is Weakness In Neuren Pharmaceuticals Limited (ASX:NEU) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

December 5, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

August 22, 2023 | msn.com

Move over Neuren – Bioshares reckons these ASX health stocks could pop with upcoming key catalysts

August 3, 2023 | msn.com

Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up

August 2, 2023 | finance.yahoo.com

Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview

July 19, 2023 | finance.yahoo.com

Are Investors Undervaluing Neuren Pharmaceuticals Limited (ASX:NEU) By 23%?

July 17, 2023 | 247wallst.com

Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here's What to Expect.

July 17, 2023 | finance.yahoo.com

Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock?

July 17, 2023 | msn.com

Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here’s What To Expect

July 14, 2023 | msn.com

Why Are Acadia Pharmaceuticals Shares Trading Higher Today?

July 14, 2023 | msn.com

Here’s Why Acadia (NASDAQ:ACAD) Stock Shot Up 23% Yesterday

May 30, 2023 | msn.com

These 3 ASX shares are in the buy zone right now

May 22, 2023 | markets.businessinsider.com

Wilsons Reaffirms Their Buy Rating on Immutep Ltd (PRRUF)

May 16, 2023 | marketwatch.com

2023 Chronic Brain Damage Treatment Market Size and Insight Report in Pharma & Healthcare Sector | with [105 Pages] and Forecast till 2031

May 16, 2023 | markets.businessinsider.com

Positive Report for Mayne Pharma Group (MAYNF) from Wilsons

May 3, 2023 | marketwatch.com

2023-2030 Global Traumatic Brain Injury Therapeutics Market is Growing Rapidly with Emerging Pattern

April 28, 2023 | marketwatch.com

Global "Traumatic Brain Injury Therapeutics Market" Growth and Outlook till 2023-2030

April 19, 2023 | marketwatch.com

2023 Phelan-McDermid Syndrome (PMS) Market Size and Growth Analysis with [86 Pages] | Exclusive Report till 2030

April 19, 2023 | morningstar.com

Regeneron Pharmaceuticals Inc REGN Stock Quote

April 11, 2023 | msn.com

See More Headlines

Receive NEU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2019
Today: 12/05/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:NEU
CUSIP: N/A
CIK: N/A
Web: www.neurenpharma.com
Phone: 61 3 9092 0480
Fax: N/A
Employees: 2,105
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A$0.44
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $55.04 million
Net Margins: 70.26%
Pretax Margin: N/A
Return on Equity: 88.06%
Return on Assets: 51.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.04
Quick Ratio: 31.54

Sales & Book Value

Annual Sales: $78.34 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 12.46
Book Value: A$0.72 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 128,970,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.60

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Jonathan Charles Pilcher A.C.A.
ACA, B.Sc., BSc (Hons), F.C.A., CEO, MD & Executive Director
Ms. Lauren Frazer C.A.
CFO & Company Secretary
Mr. Lawrence Glass BA (Biology)
Chief Science Officer
Mr. Gerry Zhao
Vice President of Corporate Development
Dr. Liza A. Squires M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders

NEU Stock Analysis - Frequently Asked Questions

How were Neuren Pharmaceuticals' earnings last quarter?: Neuren Pharmaceuticals Limited (ASX:NEU) issued its quarterly earnings results on Wednesday, February, 27th. The company reported $0.03 earnings per share for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 88.06% and a net margin of 70.26%.
What other stocks do shareholders of Neuren Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Afterpay (APT) and Alkane Resources (ALK).

This page (ASX:NEU) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial